Nomura Retains 'Buy' Rating on Company Amid Biologics Milestones
1 report, 1 independent
Updated Sep 1
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nomura retained its 'Buy' rating and Rs1,740 target price for a company on September 1, 2026. On September 28, the company's shares gained over 1% following the rating retention. The rating highlights key upcoming milestones for the company's biologics business, including potential USFDA clearance/EIR and the Abatacept action date of December 18, 2026.
From moneycontrol.com
Why it matters
The rating suggests the agency may not have serious concerns regarding the manufacturing facility, which was inspected in June 2026. The company is hopeful of a positive regulatory response in the near term regarding the outstanding observations.
From moneycontrol.com
Who's involved
- NomuraAnalyst firm that issued the rating and target price
Keep exploring
The entities involved
-
Nomura
corporation in Japan